ALN-TTRSC (RNAi) Endpoint: safety/efficacyPhase 2:open-label trial to evaluate safety, pharmacokinetics, pharmacodynamics, and Exploratory Clinical Trial of ALLN-TTRSC activity in TTR cardiac amyloidosis patients. Here, ARLN is linked to cardiac amyloidosis.